A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Inclusion Criteria

• Histologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies.
• Must not be a candidate for potentially curative therapy or standard-of-care approved therapy.
• Measurable disease by computed tomography or magnetic resonance imaging based on RECIST 1.1 as determined by site radiology.
• Eastern Cooperative Oncology Group performance status 0 to 2.
• Willingness to avoid pregnancy or fathering children.

Exclusion Criteria

• Receipt of anticancer medications, anticancer therapies, or investigational drugs within protocol-defined intervals before the first administration of study drug.
• Must have recovered (≤ Grade 2 or at pretreatment baseline) from adverse events (AEs) from previously administered therapies except for stable chronic toxicities (≤ Grade 2) not expected to resolve.
• Untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed.
• Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non-CNS disease with medical monitor approval.
• Laboratory values outside the protocol-defined range at screening.
• History or evidence of bleeding disorder or active clinically significant bleeding requiring medical intervention.